| Name | Title | Contact Details |
|---|
Cincinnati Testing Laboratory Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1978 as Immunological Associates of Denver, now known as LABS, Inc., LABS operates laboratories in Centennial, Colorado and Philadelphia, Pennsylvania. Each facility is independently certified, accredited, licensed or registered by numerous agencies that may include AABB, American Society of Histocompatibility and Immunogenetics (ASHI), the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), the U.S. Food and Drug Administration (FDA), International Organization of Standardization (ISO) and the states of California, Florida, Maryland, New York, Rhode Island and West Virginia.
Doctor's Data is a Saint Charles, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Natera Inc. is a genetic testing company that specializes in analyzing tiny quantities of DNA for reproductive health. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to analyze fetal chromosomes and understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. These tests were developed by Natera, a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.
OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. To date, we have advanced five novel anti-CSC product candidates into more than a dozen clinical studies and we continue to pursue the discovery of additional novel anti-cancer stem cell therapeutics. All of our product candidates were discovered internally in our own research laboratories. OncoMed’s discovery efforts focus on cancer stem cells, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for cancer recurrence and metastases. Our product candidates target CSCs pathways by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. We believe our product candidates are distinct from current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer. We utilize our proprietary technologies to (1) identify, isolate and evaluate CSCs, (2) identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation, and (3) develop targeted antibody and other protein-based therapeutics that are designed to modulate cancer stem cell targets and inhibit the growth of CSCs. These targets are in pathways implicated in cancer biology and stem cell biology. Our current clinical and preclinical product candidates address targets in the Notch, Wnt and RSPO pathways, as well as other undisclosed fundamental CSC pathways.